Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

Vivek Ramaswamy reacted to a list of unnecessary government expenditures that included $33 million of government expenditure to run 'Monkey Island' in South Carolina; $549K to a Russian lab ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...

The Biden administration gave Israel 30 days to increase the flow of aid, warning that aid shipments into Gaza in September had reached an alarmingly low level. By Liam Stack and Aaron Boxerman ...

Mom of 3 was brutally tortured before being set ablaze in Manipur: Autopsy A horrifying incident in Manipur's Jiribam district has left the community reeling after a 31-year-old mother of three ...

Two experimental therapies from Vicore Pharma and Endeavor BioMedicines that could provide new ways of treating idiopathic pulmonary fibrosis (IPF) have shown encouraging results in mid-stage ...

Kraft Heinz has announced it is removing its Lunchables meal kits from the National School Lunch Program. With eight $1 billion+ brands, Kraft Heinz is North America’s third-largest food and ...

Oct. 30, 2024 — Energy-making chloroplasts from algae have been inserted into hamster cells, enabling the cells to photosynthesize light, according to new research in Japan. It was previously ...

Nov. 13, 2024 — Few questions have captivated humankind more than the origin of life on Earth. How did the first living cells come to exist? How did these early protocells develop the structural ...

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O Digital ...